- The 2026 market reality check demonstrates that various Hong Kong-listed companies can no longer rely on past achievements to sustain their valuations.
- Major telecom operators face traditional business declines despite expanding into computing power, while Pop Mart confronts slowing overseas sales and a lowered growth outlook.
- Meanwhile, WuXi Biologics successfully divested non-core assets to focus on antibody-drug conjugate capacity, whereas other firms struggle with legacy issues or margin pressures.
